Old National Bancorp Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? Old National Bancorp Common Stock trades at $24.48 (market cap $9.42B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Old National Bancorp Common Stock is far larger — about 5.2× Vir Biotechnology Inc. Common Stock's market cap, and Old National Bancorp Common Stock pays a 2.36% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Old National Bancorp Common Stock for 0 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| ONB | VIR | |
|---|---|---|
Market Cap | $9.42B | $1.80B |
Volume | 4,606,260 | 1,782,836 |
Sector | Financials | Health |
52-Week High | $27.29 | $11.78 |
52-Week Low | $19.60 | $5.12 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $16.07B | $1.36B |
Dividend Yield | 2.36% | — |
Signals from Pluang's Aura AI — not financial advice
ONB trades at $24.62, down 0.73% on the day, with a neutral technical outlook and key support at $24. The company shows strong fundamentals, with a P/E of 10.89 and net income margin of 31.39%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights upcoming Q3 earnings and positive institutional investment activity.
The outlook for ONB is positive, supported by robust earnings growth and a 'Buy' consensus from analysts with a $29.67 price target. Key risks include potential earnings volatility and macroeconomic pressures on the banking sector. Upside potential exists if the company continues its trend of exceeding earnings expectations.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Old National Bancorp is the bank holding company for Old National Bank, providing consumer banking, commercial banking, wealth management, and capital markets services across Indiana, Kentucky, Michigan, Minnesota, and Wisconsin.
Read more on ONB →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →